Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 4/20 | 0.37 |
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.32 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.31 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2824650 | 1.00 | ADORA1 (0.37) | ADORA1TMIGD3ADORA2APDE4BMAP3K5 | |
| SCHEMBL2368454 | 0.97 | TMIGD3 (0.34) | ADORA1TMIGD3ADORA2APDE4BTRPA1 | |
| SCHEMBL2368446 | 0.97 | TMIGD3 (0.34) | ADORA1TMIGD3ADORA2APDE4BTRPA1 | |
| SCHEMBL13935135 | 0.90 | ADORA1 (0.36) | ADORA1TMIGD3ADORA2APDE4BPDE4D | |
| SCHEMBL13935134 | 0.90 | ADORA1 (0.36) | ADORA1TMIGD3ADORA2APDE4BPDE4D | |
| SCHEMBL13287379 | 0.90 | ADORA1 (0.34) | ADORA1TMIGD3ADORA2APDE4BMAP3K5 | |
| SCHEMBL2825309 | 0.89 | PDE4B (0.37) | ADORA1TMIGD3ADORA2APDE4BPDE4D | |
| SCHEMBL2825310 | 0.89 | PDE4B (0.37) | ADORA1TMIGD3ADORA2APDE4BPDE4D | |
| SCHEMBL2823658 | 0.89 | NPC1 (0.37) | MEN1TSHRKMT2A | |
| SCHEMBL2828452 | 0.89 | CSNK2A2 (0.32) | PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318928-B2 | Fused imidazole carboxamides as TRPV3 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2012-11-27 | — | — | US | claimed |
| US-20100152192-A1 | FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A (CH) | 2010-06-17 | — | — | US | claimed |
| US-8318928-B2 | Fused imidazole carboxamides as TRPV3 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2012-11-27 | — | — | US | disclosed |
| US-20100152192-A1 | FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A (CH) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152192-A1 | FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS | TRPV3, TRPV1, TRPV2 | ADORA1 1169/4885TMIGD3 624/4885ADORA2A 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.